Medical Laboratory Personnel Shortage Relief Act of 2024

Support clinical laboratory and allied health workforce enhancement initiatives, including but not limited to the Medical Laboratory Personnel Shortage Relief Act of 2024 (H.R.9849); support robust funding for the Centers for Disease Control Prevention's Advanced Molecular Detection program.

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

* On October 30, ADLM released a position statement on direct to consumer testing urging various federal agencies to improve the quality and oversight of such testing and to prosecute labs engaging in misleading or fraudulent practices. * On November 7, ADLM wrote to Rep. Deborah Ross endorsing H.R.9849, the Medical Laboratory Personnel Shortage Relief Act, which would use federal funding to reduce the healthcare shortage in underserved areas. * On November 20, ADLM wrote to President-elect Donald Trump's transition team urging him to withdraw the FDA's May 6, 2024 final rule regulating Laboratory Developed Tests. * On November 21, ADLM joined a coalition letter to President-elect Donald Trump's transition team urging him to withdraw the FDA's May 6, 2024 final rule regulating LDTs. * On December 10, ADLM wrote to the House and Senate Department of Government Efficiency (DOGE) caucuses urging them to support revocation of the May 6, 2024 final rule on LDTs.

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship H.R. 9849 - Medical Laboratory Personnel Shortage Relief Act of 2024 H.R. 3248 - Diagnostic Lab Testing Transparency Act H.R. 5378 - Lower Costs, More Transparency Act H.R. 2369 - the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023 H.R. 88188 - American Privacy Rights Act of 2024 Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation CMS policies related to Medicare Advantage Engagement with executive branch departments/agencies regarding influenza A (H5) "Avian Flu"

Client expense: $410,000 · Firm income: Not reported

Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE